RT Journal Article
T1 Association between dopamine and somatostatin receptor expression and pharmacological response to somatostatin analogues in acromegaly
A1 Venegas-Moreno, Eva
A1 Vazquez-Borrego, Mari C.
A1 Dios, Elena
A1 Gros-Herguido, Noelia
A1 Flores-Martinez, Alvaro
A1 Rivero-Cortes, Esther
A1 Madrazo-Atutxa, Ainara
A1 Japon, Miguel A.
A1 Luque, Raul M.
A1 Castano, Justo P.
A1 Cano, David A.
A1 Soto-Moreno, Alfonso
K1 Acromegaly
K1 Pituitary adenoma
K1 Somatostatin receptor
K1 Dopamine receptor
K1 Somatostatin analogues
AB Acromegaly is a hormonal disorder resulting from excessive growth hormone (GH) secretion frequently produced by pituitary adenomas and consequent increase in insulin-like growth factor 1 (IGF-I). Elevated GH and IGF-I levels result in a wide range of somatic, cardiovascular, endocrine, metabolic and gastrointestinal morbidities. Somatostatin analogues (SSAs) form the basis of medical therapy for acromegaly and are currently used as first-line treatment or as second-line therapy in patients undergoing unsuccessful surgery. However, a considerable percentage of patients do not respond to SSAs treatment. Somatostatin receptors (SSTR1-5) and dopamine receptors (DRD1-5) subtypes play critical roles in the regulation of hormone secretion. These receptors are considered important pharmacological targets to inhibit hormone oversecretion. It has been proposed that decreased expression of SSTRs may be associated with poor response to SSAs. Here, we systematically examine SSTRs and DRDs expression in human somatotroph adenomas by quantitative PCR. We observed an association between the response to SSAs treatment and DRD4, DRD5, SSTR1 and SSTR2 expression. We also examined SSTR expression by immunohistochemistry and found that the immunohistochemical detection of SSTR2 in particular might be a good predictor of response to SSAs.
PB Wiley-Blackwell Publishing
YR 2017
FD 2017-09-27
LK http://hdl.handle.net/10668/18991
UL http://hdl.handle.net/10668/18991
LA en
NO Venegas-Moreno E, Vazquez-Borrego MC, Dios E, Gros-Herguido N, Flores-Martinez A, Rivero-Cortés E, et al. Association between dopamine and somatostatin receptor expression and pharmacological response to somatostatin analogues in acromegaly. J Cell Mol Med. 2018 Mar;22(3):1640-1649
NO This work was supported by grants from the ISCIII-Subdireccion General de Evaluaci on y Fomento de la Investigacion co-funded with Fondos FEDER (PI13/02043 to A.S-M. and PI16/00175 to A.S-M. and D.A.C), Novartis Oncology Spain (to A.S-M.), Junta de Andalucıa (A-0023-2015, A0003-2016 to A.S-M. and CTS-1406, BIO-0139; PI-639-2012, PI-0541-2013 toR.M.L and J.P.C.), MINECO (BFU2013-43282-R, BFU2016-80360-R to J.P.C.)and CIBERobn (CIBER is an initiative of Instituto de Salud Carlos III, Ministeriode Sanidad, Servicios Sociales e Igualdad, Spain) to R.M.L and J.P.C. Part ofthe analyses included in this study was carried out within the REMAH (‘Spanish molecular registry of pituitary adenomas’) project, supported byNovartis Oncology as well as by the Andalusian and Spanish Societies ofEndocrinology and Nutrition (SAEDYN and SEEN). D.A.C. was supported by aresearch contract from the ‘Nicol as Monardes’ programme of the AndalusianMinistry of Health (C-0015-2014). This research has been conducted usingsamples from the HUVR-IBiS Biobank (Andalusian Public Health System Bio bank and ISCIII-Red de Biobancos PT13/0010/0056). The authors thank the donors for the human specimens used in this study.
DS RISalud
RD Apr 14, 2025